FG
PRCT icon

Fairman Group’s Procept Biorobotics PRCT Stock Holding History

Fairman Group’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.6K Hold
1,000
– – 0.02% 136
2026
Q1 		$25K Sell
1,000
-1,000
-50% -$28.2K 0.02% 121
2025
Q4 		$62.9K Hold
2,000
– – 0.05% 96
2025
Q3 		$71.4K Hold
2,000
– – 0.06% 90
2025
Q2 		$115K Hold
2,000
– – 0.09% 68
2025
Q1 		$161K Hold
2,000
– – 0.15% 62
2024
Q4 		$161K Hold
2,000
– – 0.13% 66
2024
Q3 		$160K Hold
2,000
– – 0.14% 66
2024
Q2 		$122K Hold
2,000
– – 0.12% 73
2024
Q1 		$98.8K Hold
2,000
– – 0.09% 73
2023
Q4 		$83.8K Buy
+2,000
New +$68.1K 0.08% 81

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fairman Group's PRCT Position: Q2 2026 in Review

Fairman Group held its Procept Biorobotics (PRCT) position steady in Q2 2026 at 1,000 shares worth $22.6K. The position accounts for 0.02% of the portfolio, ranked #136.

Fairman Group first reported a position in PRCT in Q4 2023 and has held it in 11 quarters since. The position peaked at $161K in Q1 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Fairman Group held 1,000 shares of Procept Biorobotics worth $22.6K as of Q2 2026.
  • Fairman Group left its Procept Biorobotics share count unchanged in Q2 2026.
  • Procept Biorobotics made up 0.02% of Fairman Group's portfolio in Q2 2026, its #136 holding.
  • Fairman Group first reported a position in Procept Biorobotics in Q4 2023 and has held it in 11 quarters since.
  • Fairman Group's Procept Biorobotics position peaked at $161K in Q1 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Fairman Group's 13F filing for Q2 2026, filed 4 Aug 2026.